E

Evofem Biosciences Inc
F:1AQ1

Watchlist Manager
Evofem Biosciences Inc
F:1AQ1
Watchlist
Price: 0.1432 EUR -2.59% Market Closed
Market Cap: €65.8m

Operating Margin

-125.7%
Current
Improving
by 91.1%
vs 3-y average of -216.8%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-125.7%
=
Operating Income
$-17.1m
/
Revenue
$16m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-125.7%
=
Operating Income
€-17.1m
/
Revenue
$16m

Peer Comparison

Country Company Market Cap Operating
Margin
US
Evofem Biosciences Inc
F:1AQ1
65.8m EUR
Loading...
US
Eli Lilly and Co
NYSE:LLY
969.6B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
547.3B USD
Loading...
CH
Roche Holding AG
SIX:ROG
277.1B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
209.4B GBP
Loading...
CH
Novartis AG
SIX:NOVN
219B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
271.3B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
148.3B USD
Loading...
FR
Sanofi SA
PAR:SAN
93.8B EUR
Loading...

Market Distribution

Lower than 86% of companies in the United States of America
Percentile
14th
Based on 14 112 companies
14th percentile
-125.7%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Evofem Biosciences Inc
Glance View

Market Cap
65.8m EUR
Industry
Pharmaceuticals

Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company, which develops and commercializes innovative products to unmet needs in women's sexual and reproductive health. The company is headquartered in San Diego, California and currently employs 119 full-time employees. The company went IPO on 2014-11-20. The company is engaged in developing and commercializing products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). Its product, Phexxi vaginal gel, is a hormone-free, woman-controlled, on-demand prescription contraceptive gel for women. Its lead clinical program is evaluating Phexxi (using the investigational name EVO100) for the prevention of chlamydia and gonorrhea in women. EVO200 vaginal gel (EVO200), its investigational candidate for the reduction of recurrent bacterial vaginosis (BV), uses the same vaginal potential of hydrogen (pH) modulator platform as Phexxi. The company also focuses on developing Multipurpose Prevention Technology (MPT) vaginal gel for indications, including the prevention of human immunodeficiency virus (HIV) in women through Orion Biotechnology Canada Ltd.

1AQ1 Intrinsic Value
Not Available
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-125.7%
=
Operating Income
$-17.1m
/
Revenue
$16m
What is Evofem Biosciences Inc's current Operating Margin?

The current Operating Margin for Evofem Biosciences Inc is -125.7%, which is above its 3-year median of -216.8%.

How has Operating Margin changed over time?

Over the last 1 years, Evofem Biosciences Inc’s Operating Margin has increased from -346.4% to -125.7%. During this period, it reached a low of -346.4% on Mar 3, 2023 and a high of -108.3% on Dec 31, 2023.

Back to Top